Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose Atuliflapon in adults with moderate-to-severe uncontrolled asthma
2021-003338-35Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atuliflapon in asthma (5 arms), sponsored by AstraZeneca. Primary endpoint: Time to first CompEx Asthma event. Started Mar 2022; status: active.
02
Drugs
atuliflapon
03
Conditions
asthma
Beyond the preview
Go deeper on 2021-003338-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003338-35.